Compare JPMorgan Equity Premium Income ETF (JEPI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Revvity Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.85, while Revvity Inc trades at $117.95 (market cap $13.15B). The key difference: Revvity Inc pays a 0.24% dividend while JPMorgan Equity Premium Income ETF pays none, and Revvity Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPI | RVTY | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $59.88 | $117.88 |
52-Week Low | $55.29 | $82.26 |
Market Cap | — | $13.15B |
Enterprise Value | — | $15.47B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $57.84, up 0.35% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent dividends of $0.39 and $0.37 highlight its income focus, while news coverage emphasizes its role in retirement portfolios amid competitive yield pressures from peers like SPYI and JEPQ.
The outlook is mixed: strong income appeal supports demand, but underperformance versus covered-call peers and tax inefficiencies risk long-term returns. Investors face trade-offs between monthly distributions and capital appreciation, with sentiment divided on whether JEPI's strategy justifies opportunity costs.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
